Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

This Ultra-High-Yield Dividend Stock's Investors Can Breathe a Sigh of Relief


Shares of AT (NYSE: T) have fallen more than 25% from their 52-week high. Weighing on the telecom giant's stock is concerns about its free cash flow. That has caused some worries that it might not be able to maintain its lofty dividend, which now yields more than 7% following its share price decline.

However, dividend investors can breathe a bit easier after AT's CFO recently said the company is on track to achieve its free cash flow guidance for the year. That suggests the dividend won't see another reduction in the near term. Nevertheless, that doesn't mean income-focused investors should rush out and buy its stock.

AT's CFO Pascal Desroches recently affirmed the company would produce between $4.5 billion and $5 billion of free cash flow during the third quarter. That gave the CFO the confidence to reiterate the company's guidance that it would generate AT least $16 billion in free cash this year. 

Continue reading


Source Fool.com

Allergy Therapeutics PLC Aktie

0,062 €
6,03 %
Ein erheblicher Kursanstieg bei Allergy Therapeutics PLC heute, um 6,03 %.

Like: 0
T
Teilen

Kommentare